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A B S T R A C T
Policosanol is an agent that includes mixtures of aliphatic primary alcohols extracted primarily from sugercane wax.
Policosanol has been shown to lower total and LDL cholesterol in animal models, healthy volunteers and hypercho-
lesterolemic patients. However, these findings have been challanged recently. Up to now, there has been no study investi-
gating the effects of policosanol on blood coagulation factors.This study investigated the effects of rice policosanol (Oryza
sp.) 10 mg/day on blood coagulation factors in 66 hypercholesterolemic patients of both sexes aged 20 to 78 years in a sin-
gle center, randomized, double-blind, placebo-controlled, crossover trial. After an 8-week run-in period in which patients
were placed on therapeutic lifestyle changes, in particular a cholesterol-lowering diet, they were randomly assigned to re-
ceive rice policosanol 10 mg tablets or placebo tablets once daily with the evening meal for 8 weeks. During next 8 weeks
those receiving policosanol during the first 8 weeks, received placebo and those taking placebo during the first 8 weeks,
received policosanol. Plasma fibrinogen, factors VII,VIII, XII and XIII were measured before and after the treatment.
Rice policosanol treatment did not change significantly neither fibrinogen nor factors VII,VIII, XII and XIII.
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Introduction
Policosanol is a natural mixture of long-chain primary
aliphatic alcohols extracted primarily from sugarcane
(Saccharum officinarum L) wax. Its main components
are octacosanol (62.9%), triacontanol (12.6%) and hexa-
cosanol (6.2%).1 Sugarcane policosanol has been reported
to lower total and LDL-cholesterol in healthy volunteers2
and in patients with hypercholesterolemia of all ages3–8
as well as to increase slightly HDL-cholesterol3,5,10. The
results of several trials with sugar cane policosanol even
suggested similar efficacy with established lipid-lowering
drugs, such as statins.7,11–13 Other effects attributed to
policosanol are antithrombotic and antioxidant actions.
We have recently shown that rice policosanol has
much fewer effect on total cholesterol and no significant
effect on LDL-cholesterol, HDL-cholesterol, triglyceri-
des, Ox-LDL, HDL2-cholesterol, HDL3-cholesterol, apo-
protein B, lipoprotein (a), homocysteine and C-reactive
protein.14
Since so far there were no trials investigating the ef-
fects of policosanol from any origin on blood coagulation
factors, the aim of this study was to investigate the ef-
fects of rice policosanol on plasma fibrinogen, and blood
coagulation factors VII, VIII, XII and XIII.
Patients and Methods
Patients and study design
66 patients of both sexes (23 males and 43 females)
age range 20 to 78 years (median age 53 years) with a
documented type II a or II b hypercholesterolemia who
were not taking any antiplatelet or anticoagulation drug
therapy participated in the study. A randomized, dou-
ble-blind, placebo-controlled, crossover study design in
two phases was used at intervals of 8 weeks. A complete
medical history was taken and a physical examination
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was performed prior to the study in all patients. The eli-
gibility characteristics of patients were assessed during
an 8 week dietary (American Heart Association/National
Cholesterol Education Program step 1 diet) baseline pe-
riod prior to randomization, while the participants were
off all lipid-lowering medications. The same diet was
maintained throughout the treatment period. For pa-
tients who were not treatment-naive, a 8-week wash-out
period for all classes of lipid-lowering treatment was
mandatory prior to start of the dietary run-in.
All participants provided written informed consent,
and the study was approved by the Ethics committee of
the University Hospital Center Zagreb, Croatia.
The lipid entry criteria were: total cholesterol of ³ 5
mmol/L (190 mg/dL) to 10 mmol/L (390 mg/dL) and/or
LDL-cholesterol of ³ 3 mmol/L (110 mg/dL) to 8 mmol/L
(310 mg/dL). Triglyceride concentration had to be ³2
mmol/L (180 mg/dL) to 10 mmol/L (890 mg/dL). All but
two subjects were nonsmokers.
The exclusion criteria were: increased alcohol con-
sumption (>21 units per week), unregulated diabetes,
obesity (body mass index >30), pregnant or lactating
women, clinical hypo- or hyperthyroidism, clinical liver
or renal disease, chronic or acute pancreatitis, former or
present malignant disease, autoimmune diseases, history
of myocardial infarction, angioplasty or other major sur-
gery within 6 months prior to entry, antiplatelet or
anticoagulation drug therapy.
After randomization the subjects were instructed to
take identical 10 mg placebo capsule or 10 mg rice
policosanol (Oryza sp.) wax capsule once daily with their
evening meal for 8 weeks. During next 8 weeks those re-
ceiving policosanol during the first 8 weeks, received pla-
cebo and those taking placebo during the first 8 weeks,
received policosanol. Drug compliance was assessed by
tablet count and interviews with the patients.
Laboratory analysis
Laboratory tests were performed at the beginning of
the study, after the diet period, i.e. before taking the cap-
sules, after the first 8 weeks of treatment and after the
second 8 weeks of treatment. The following parameters
were measured: total cholesterol, LDL cholesterol, HDL
cholesterol, triglycericerides, fibrinogen, blood coagula-
tion factors. All blood samples were drawn between 8:00
AM and 9:00 AM after an overnight fast of 12 hours, and
aliquots were obtained for laboratory determinations.
Serum concentrations of cholesterol and triglycerides
were measured by standard enzymatic methods using
commercial kits from Boehringer Mannheim Diagno-
stica. Serum concentration of HDL cholesterol was mea-
sured after precipitation with phosphotungstic acid and
magnesium chloride.15 Fibrinogen was measured by coa-
gulometry16, factors VII, VIII and XII by coagulometry
using Innovin and Actin FS17, and factor XIII by photom-
etry using a chromogenic substrate – Berichrom Hepa-
rin, Dade Behring.18
Statistical analysis
The validity of crossover design was checked on HDL
cholesterol. The results showed acceptable validity of
crossover design (period effect: t=0.30; df=65; p=0.768
and treatment-period interaction: t=1.36; df=65; p=
0.178).
All data were analyzed according to the intent-to-
treat principle; thus, available data from patients who
withdrew from the study were included in all analyses.
Results
After the 8-week diet-only period 70 of 78 patients ini-
tially recruited were included in the study; of these 66
completed the study. The reasons for withdrawals were
unwillingness to follow up during the placebo period and
change of residence during the treatment period. Com-
pliance as assessed by capsules count and patient inter-
views was >95%.
Rice policosanol 10 mg /day did not significantly re-
duce plasma neither fibrinogen, nor coagulation factors
VII, VIII, XII and XIII (Table 1).
With regards to the effects of policosanol treatment
on safety parameters, no significant differences from
baseline values were observed for systolic or diastolic
blood pressure, glucose, creatinin, bilirubin, serum ami-
notransferases or CK.
Discussion
This study demonstrates that rice policosanol admin-
istered at the dose of 10 mg daily does not have any sig-
nificant effect on fibrinogen or blood coagulation factors.
Rice policosanol treatment did not result in any adverse
effects as indicated by reports of the patients, physical
examinations and plasma activities of glucose, creatinin,
bilirubin, AST, ALT,GGT and CK.
Despite very optimistic results of about 30 trials pub-
lished virtually all by a single research group from Cuba,
showing significant lipid lowering effects of sugercane
policosanol, four recent studies have challanged these
findings.19–22 In a randomised, double-blind, placebo-con-
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TABLE 1
EFFECT OF RICE POLICOSANOL ON SOME BLOOD
COAGULATION FACTORS
Parameter N Baseline
After
treatment
p –
Value
Fibrinogen 66 3.89±0.78 3.90±0.96 0.356
Factor VII 65 1.14±0.27 1.16±0.33 0.653
Factor VIII 65 1.85±0.67 1.86±0.56 0.769
Factor XII 64 1.09±0.30 1.07±0.31 0.455
Factor XIII 66 1.23±0.23 1.27±0.23 0.188
Data are given as mean±SD
trolled study we have also recently shown that rice
policosanol (Oryza sp.) has much fewer effect on total
cholesterol than claimed by the Cuban authors for suger-
cane policosanol, and no significant effect on LDL-cho-
lesterol, HDL-cholesterol and triglycerides as well as no
effect on Ox-LDL, HDL2 cholesterol, HDL3 cholesterol,
apoprotein B, lipoprotein (a), homocysteine and C-reac-
tive protein.14 A clinical trial performed with wheat
germ-derived policosanol could also not find any signifi-
cant effects on total cholesterol, LDL-cholesterol, HDL-
cholesterol or triglycerides.23
Up to now, there has been no study demonstrating
significant efficacy of policosanol from any origin on clin-
ical cardiovascular disease (CVD) endpoints. Only two
Cuban studies with sugarcane policosanol demonstrated
an improvement of initial and absolute claudication dis-
tance.24,25
It is well known that conventional risk factors such as
hypercholesterolemia do not fully account for the occur-
rence of atherothrombotic vascular disease. Haemostatic
factors associated with biological systems regulating pla-
telets, coagulation and fibrinolysis seem to be closely as-
sociated with the development of coronary heart disease
(CHD) and cardiovascular events such as myocardial in-
farction (MI) and stroke. For example increased fibrino-
gen seems to be associated not only with CHD26–31 but
also with peripheral vascular disease32 and stroke.33 The
association of coagulation factors and cardiovascular dis-
eases remains incompletely understood.
F VII is an initiator of extrinsic blood coagulation. F
VII clotting activity, despite initial observations that it
might be a risk factor for CHD, especially in the presence
of other risk factors34, at least seems not to be a factor in-
dependent of other risk factors. 28,29 However, several au-
thors have not proved any significant changes of F VII in
patients with CHD31 or any relationship between F VIIc
levels and severity of atheroma.35
F VIII seems to be associated with CHD and mortality
in men, as well as with stroke and transitory ischaemic
attacks (TIA) in women.36–38 An association of F VIII an-
tigen but not F VIII coagulation activity with MI has
been also noticed.39
F XII is an initiator of intrinsic blood coagulation. It is
activated in contact with various biologic surfaces, in-
cluding subendothelial tissues and lipoprotein particles
which suggests its possible role in atherothrombosis. It
has been shown that activated F XII (F XIIa) is involved
in vascular injury and repair, participating in inflamma-
tion, thrombosis and fibrinolysis. Although it is under
strong genetic control it reflects plasma triglycerides and
endothelial activation/dysfunction. Some authors have
found that F XII could predict recurrent coronary events
after MI40 and that plasma F XIIa, which is an initial
product of contact activation, is increased in men at high
risk of CHD.41 Others claim that F XII is not a predictor
of coronary events and has no relationship with CHD
whatsoever.42,43 Anyhow, F XIIa appears unlikely to be di-
rectly atherogenic. However, TT genotype of F XII 46C>
T polymorphism, which determines FXII levels, seems to
be associated with a high CHD risk in subjects with hy-
percholesterolemia.44
There are few studies indicating that higher F XIII
levels might be associated with increased risk of MI.45,46
On the other hand, it has been observed that F XIII Val
34 Leu polymorphism is associated with a significant
protective effect against the occurrence of MI.47
There are no data in the literature on possible effects
of policosanol on blood coagulation factors. Only two
studies performed with sugarcane policosanol indicated
that this substance might induce modest reduction of
fibrinogen.13,25 We could not confirm such an effect with
rice policosanol neither could we prove any effect of rice
policosanol on the investigated coagulation factors.
Conclusion
We can conclude that rice policosanol 10 mg/day does
not have any significant effect on plasma fibrinogen, co-
agulation factors VII,VIII, XII and XIII.
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POLIKOZANOL IZ RI@E NEMA NIKAKVIH U^INAKA NA ^IMBENIKE ZGRU[AVANJA
KRVI U BOLESNIKA S HIPERKOLESTEROLEMIJOM
S A @ E T A K
Polikozanol je mje{avina alifatskih primarnih alkohola koja se poglavito ekstrahira iz {e}erne trske. Pokazano je da
polikozanol smanjuje ukupni i LDL kolesterol u pokusnih `ivotinja, zdravih dragovoljaca i bolesnika s hiperkolestero-
lemijom. Me|utim, nedavno je to dovedeno pod znak sumnje. Do danas jo{ nije na~injeno istra`ivanje u kojem bi se
ispitali u~inci polikozanola na ~imbenike zgru{avanja. U ovom su istra`ivanju ispitani u~inci polikozanola iz ri`e (Ory-
za sp.) u dozi od 10 mg/dan na ~imbenike zgru{avanja u 66 bolesnika oba spola s hiperkolesterolemijom starih izme|u
20 i 78 godina. To je randomizirano, dvostruko slijepo, placebom kontrolirano, kri`no ispitivanje provedeno u jednom
centru. Nakon razdoblja od 8 tjedana tijekom kojih su se bolesnici pridr`avali promijenjenog na~ina `ivota, poglavito
dijete za sni`avanje kolesterola u krvi, randomizirani su da uzimaju kapsule sa 10 mg polikozanola ili placeba jednom
dnevno uz ve~ernji obrok tijekom 8 tjedana. Tijekom slijede}ih 8 tjedana oni koji su prvih 8 tjedana uzimali polikozanol,
uzimali su placebo i obratno, oni koji su prvih 8 tjedana dobivali placebo, uzimali su polikozanol. Prije i nakon lije~enja
odre|ivani su im fibrinogen, te ~imbenici zgru{avanja VII,VIII, XII i XIII u plazmi. Uzmanje polikozanola iz ri`e nije
uzrokovalo nikakve zna~ajnije promjene ni fibrinogena ni ~imbenika VII,VIII, XII i XIII.
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